Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988605 · ClinicalTrials.gov registry record
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
A clinical trial of Atopic Dermatitis, sponsored by Galderma R&D.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 20
- Study locations
NCT06988605: Recruiting study of Atopic Dermatitis, sponsored by Galderma R&D.
NCT06988605 is a study of Atopic Dermatitis that is actively recruiting participants, run by Galderma R&D. The registered enrollment target is 1,000 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06988605, a study of Atopic Dermatitis, is actively recruiting participants, sponsored by Galderma R&D.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Primary Outcome
The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the investigator or trained designee to evaluate the global severity of AD and the clinical response to a treatment.
Conditions Studied
Study Locations (20)
California
- Galderma Investigational Site - 7074 - Corona
- Galderma Investigational Site 8636 - Fountain Valley
- Galderma Investigational Site 8224 - Fremont
- Galderma Investigational Site 7099 - Los Angeles
- Galderma Investigational Site 8553 - Newport Beach
- Galderma Investigational Site 7064 - Santa Monica
- Galderma Investigational Site 7107 - Thousand Oaks
Florida
- Galderma Investigational Site 8597 - Boca Raton
- Galderma Investigational Site 7087 - Coral Gables
- Galderma Investigational Site 7063 - Cutler Bay
- Galderma Investigational Site 7134 - Hollywood
- Galderma Investigational Site 7101 - Jupiter
- Galderma Investigational Site 7078 - Miami
Arizona
- Galdrma Investigational Site - 7077 - Phoenix
- Galderma Investigational Site 7060 - Phoenix
- Galderma Investigational Site - 8535 - Phoenix
- Galderma Investigational Site - 7067 - Tucson
Alabama
- Galderma Investigational Site - 8893 - Birmingham
Colorado
- Galderma Investigational Site 7061 - Castle Rock
Connecticut
- Galderma Investigational Site 7059 - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2027-11-30 |
What NCT06988605 shows while recruiting
NCT06988605 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (66% higher).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.
NCT06988605 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06988605 about?
NCT06988605 is a clinical study titled "Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults". The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
What is the current status of trial NCT06988605?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-07-14. Estimated completion is 2027-11-30.
What conditions does trial NCT06988605 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
Who is sponsoring clinical trial NCT06988605?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06988605 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06988605's enrollment target sits among peer trials
1,000 11th of 150 higher than 139 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI